

MK-0916

Chemical Properties


CAS No. : 633317-53-0

Formula: C₁₈H₁₉ClFN₃

Molecular Weight: 331.82

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

Description	MK-0916 is a 11β-hydroxysteroid dehydrogenase type 1 inhibitor indicated for the treatment of type 2 diabetes and metabolic syndrome as well as obesity-related diseases.
Targets(IC50)	Others

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.0137 mL	15.0684 mL	30.1368 mL
5 mM	0.6027 mL	3.0137 mL	6.0274 mL
10 mM	0.3014 mL	1.5068 mL	3.0137 mL
50 mM	0.0603 mL	0.3014 mL	0.6027 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Harno E, Cottrell EC, Yu A, DeSchoolmeester J, Gutierrez PM, Denn M, Swales JG, Goldberg FW, Bohlooly-Y M, Andersén H, Wild MJ, Turnbull AV, Leighton B, White A. 11 β -Hydroxysteroid dehydrogenase type 1 (11 β -HSD1) inhibitors still improve metabolic phenotype in male 11 β -HSD1 knockout mice suggesting off-target mechanisms. *Endocrinology*. 2013 Dec;154(12):4580-93. doi: 10.1210/en.2013-1613. Epub 2013 Oct 29. PubMed PMID: 24169553; PubMed Central PMCID: PMC4192288.

Wright DH, Stone JA, Crumley TM, Wenning L, Zheng W, Yan K, Yang AY, Sun L, Cilissen C, Ramael S, Hermanowski-Vosatka A, Langdon RB, Gottesdiener KM, Wagner JA, Lai E. Pharmacokinetic-pharmacodynamic studies of the 11 β -hydroxysteroid dehydrogenase type 1 inhibitor MK-0916 in healthy subjects. *Br J Clin Pharmacol*. 2013 Dec;76(6):917-31. doi: 10.1111/bcp.12131. PubMed PMID: 23594227; PubMed Central PMCID: PMC3845315.

Anagnostis P, Katsiki N, Adamidou F, Athyros VG, Karagiannis A, Kita M, Mikhailidis DP. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders? *Metabolism*. 2013 Jan;62(1):21-33. doi: 10.1016/j.metabol.2012.05.002. Epub 2012 May 30. Review. PubMed PMID: 22652056.

Shah S, Hermanowski-Vosatka A, Gibson K, Ruck RA, Jia G, Zhang J, Hwang PM, Ryan NW, Langdon RB, Feig PU. Efficacy and safety of the selective 11 β -HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension. *J Am Soc Hypertens*. 2011 May-Jun;5(3):166-76. doi: 10.1016/j.jash.2011.01.009. Epub 2011 Mar 21. PubMed PMID: 21419745.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481